Avantor (NYSE:AVTR) Trading Down 2.7%

Avantor, Inc. (NYSE:AVTR) traded down 2.7% during mid-day trading on Friday . The stock traded as low as $20.66 and last traded at $20.72. 778,503 shares were traded during trading, a decline of 86% from the average session volume of 5,720,703 shares. The stock had previously closed at $21.29.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Barclays cut their price target on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a report on Friday, June 28th. Evercore ISI dropped their target price on shares of Avantor from $28.00 to $27.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Deutsche Bank Aktiengesellschaft increased their target price on shares of Avantor from $23.00 to $25.00 and gave the company a “hold” rating in a report on Thursday, April 18th. Citigroup cut shares of Avantor from a “buy” rating to a “neutral” rating and dropped their target price for the company from $30.00 to $23.00 in a report on Wednesday. Finally, Robert W. Baird dropped their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, April 29th. Five investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, Avantor has an average rating of “Moderate Buy” and an average target price of $25.79.

Avantor Stock Performance

The stock’s 50-day moving average is $23.07 and its 200-day moving average is $23.69. The stock has a market cap of $14.09 billion, a price-to-earnings ratio of 54.58, a price-to-earnings-growth ratio of 2.12 and a beta of 1.32. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.61 and a quick ratio of 1.05.

Avantor (NYSE:AVTR) last announced its earnings results on Friday, April 26th. The company reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.02. Avantor had a net margin of 3.79% and a return on equity of 13.01%. The firm had revenue of $1.68 billion for the quarter, compared to analyst estimates of $1.68 billion. During the same quarter last year, the business earned $0.29 earnings per share. Avantor’s revenue was down 5.6% compared to the same quarter last year. Analysts anticipate that Avantor, Inc. will post 1.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Avantor

Hedge funds have recently made changes to their positions in the stock. Versant Capital Management Inc raised its stake in shares of Avantor by 2,003.6% in the 2nd quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock valued at $25,000 after acquiring an additional 1,102 shares during the period. Fifth Third Bancorp raised its stake in shares of Avantor by 125.3% in the 4th quarter. Fifth Third Bancorp now owns 1,248 shares of the company’s stock valued at $28,000 after acquiring an additional 694 shares during the period. Livforsakringsbolaget Skandia Omsesidigt raised its stake in shares of Avantor by 565.5% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,331 shares of the company’s stock valued at $30,000 after acquiring an additional 1,131 shares during the period. Gladius Capital Management LP purchased a new position in shares of Avantor in the 4th quarter valued at $42,000. Finally, Montag A & Associates Inc. purchased a new position in shares of Avantor in the 4th quarter valued at $43,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.